Craig-Hallum analyst Matt Hewitt raised the firm’s price target on Ligand to $140 from $135 and keeps a Buy rating on the shares following the acquisition of Apeiron for $100M in cash. The acquisition will have a positive financial impact on the company, and it will put the company ahead of plan regarding their target of $10+ in EPS in 2028, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND:
- Ligand Pharma Expands Portfolio with APEIRON Acquisition and Investment
- Ligand raises FY24 EPS view to $5.00-$5.50 from $4.25-$4.75,consensus $4.64
- Ligand: APEIRON acquisition immediately accretive to EPS by $1 annualized
- Ligand to acquire APEIRON Biologics AG for $100M cash
- Ligand earns $5.8M milestone payment following FDA approval of Ohtuvayre